Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation

REMAIN-1 Pivotal Topline Six-Month Results

Commercial Strategy Event

REMAIN-1 Midpoint Cohort One-Year Results

REVEAL-1 One-Year Results

Minimum 15 minutes delayed. Source: LSEG

News Releases

Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026

Nov 6, 2026

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

Oct 30, 2026

Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance

Oct 29, 2026

Events

Fractyl Health 3Q 2026 Financial Results and Business Update Conference

Nov 12, 2026 | 4:30 PM EST

Topline Results for Pivotal REMAIN-1 Study Conference Call

Oct 16, 2026 | 8:00 AM EDT

SEC Filings

Report of unscheduled material events or corporate event

Oct 22, 2026 | Form Type: 8-K

Oct 22, 2026

Report of unscheduled material events or corporate event

Oct 16, 2026 | Form Type: 8-K

Oct 16, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200